Author summary Why was this study done? Radical cure with primaquine or recently approved tafenoquine is required to clear the dormant liver parasites of vivax malaria. While single-dose tafenoquine overcomes the barrier of patient adherence to the current 7-day primaquine treatment, it costs more and requires screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency. While the impact of changing policies to tafenoquine after G6PD screening on transmission has been evaluated, the associated costs and cost-effectiveness will be important considerations for policymakers. What did the researchers find? Using an economic evaluation model coupled with a transmission model, we found that prescribing tafenoquine to vivax malaria patients without G6PD deficiency would be highly likely to be cost-effective in Brazil. Tafenoquine will be particularly cost-effective in settings where patient adherence to the current 7-day treatment is low and when paediatric tafenoquine is available
In this retrospective analysis, Aye Sandar Zaw and colleagues report the successful elimination of falciparum malaria following the introduction of community-based health workers in Eastern Myanmar
Katrine Finderup Nielsen and colleagues investigate vaccine effectiveness against SARS-CoV-2 reinfection, COVID-19 related hospitalization and COVID-19 related death, in previously infected individuals in Denmark.
Katrine Finderup Nielsen and colleagues investigate vaccine effectiveness against SARS-CoV-2 reinfection, COVID-19 related hospitalization and COVID-19 related death, in previously infected individuals in Denmark.
In this multi-centre cohort study from Switzerland, Dr Christian R. Kahlert and colleagues investigate the risk and symptoms of COVID-19 among healthcare professionals, according to baseline immune status and booster vaccination, during the Delta and Omicron waves.